A Phase 1b Open Label Study to Evaluate the Safety and Anti cancer Activity of Loncastuximab Tesirine in Combination with Other Anti cancer Agents in Patients with Relapsed or Refractory B cell Non Hodgkin Lymphoma (LOTIS 7)
For more information about the trial above please contact the study team:
Principal Investigator, Brian Hess, at firstname.lastname@example.org.
Study Coordinator, Sarah Britton, at email@example.com, or please call +1 843-792-8057.
Trial opened at the following institutions: Medical University of South Carolina